Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Travoprost Intraocular Implant, high elution
Travoprost Intraocular, high elution · 1 trial · 1 indication
Change from baseline in IOP (measured in mmHg) at week 12. Negative values represent reductions in IOP from baseline.
| Arm | Type | Description |
|---|---|---|
| Travoprost Intraocular Implant, high elution | EXPERIMENTAL | This implant will be surgically implanted and elute travoprost, a prostaglandin. |
| Travoprost Intraocular Implant, low elution | EXPERIMENTAL | This implant will be surgically implanted and elute travoprost, a prostaglandin. |
| Timolol Maleate Ophthalmic Solution, 0.5% | ACTIVE_COMPARATOR | Timolol, a beta blocker, will be dosed twice daily |
| Name | Type | Description |
|---|---|---|
| Travoprost Intraocular Implant, high elution | DRUG | Surgical implant placed within the eye to elute travoprost. |
| Travoprost Intraocular Implant, low elution | DRUG | Surgical implant placed within the eye to elute travoprost |
| Timolol Maleate Ophthalmic Solution, 0.5% | DRUG | Instillation of one drop of timolol in the study eye twice daily |
Inclusion Criteria: * Open angle glaucoma Exclusion Criteria: * Uveitic, neovascular, or angle closure glaucoma; or glaucoma associated with vascular disorders. * Functionally significant visual field loss, including severe nerve fiber bundle defects. * Prior glaucoma surgery. * Uncontrolled syst...
Travoprost intraocular, high elution is an investigational small molecule therapy being developed by Glaukos Corporation for open-angle glaucoma. It is designed as an intraocular implant that delivers travoprost, a prostaglandin analog, into the eye. It is not yet approved and remains in clinical development.
Travoprost intraocular, high elution is being studied for the treatment of open-angle glaucoma. The condition involves elevated intraocular pressure that can damage the optic nerve. The implant is intended to provide sustained delivery of travoprost to lower eye pressure in patients with this form of glaucoma.
Travoprost intraocular, high elution targets PTGFR, the prostaglandin F receptor. It acts as an agonist at this receptor. Activation of PTGFR increases aqueous humor outflow from the eye, which lowers intraocular pressure. This mechanism is consistent with its development for open-angle glaucoma.
Travoprost intraocular, high elution is being developed by Glaukos Corporation, which trades under the ticker GKOS. Glaukos is an ophthalmology-focused company. The asset is part of its pipeline of sustained-release therapies for eye conditions, including open-angle glaucoma.
Travoprost intraocular, high elution is in Phase 2 development. It is investigational and has not been approved by the FDA. The Phase 2 trial has been completed, and no active trials are currently listed for this asset.
Travoprost intraocular, high elution has been evaluated in one completed Phase 2 trial, NCT02754596, titled "Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution." The trial enrolled 154 participants with open-angle glaucoma in the United States. It was randomized, double-blind, and active-controlled.
Yes, travoprost intraocular, high elution is also known as travoprost intraocular implant, high elution. Both names refer to the same investigational Glaukos Corporation asset for open-angle glaucoma. The alternative name emphasizes the implant-based delivery form of the therapy.